Aeglea BioTherapeutics, Inc.
Ticker
AGLE
ISIN
US00773J103
Price
-
Change Today
-
Price 1 year ago
-
Market Capitalization
25,547,760.00
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NGM
Earnings Per Share
-1.516
P/E Ratio
-
Debt/Equity Ratio
7.999
Beta
1.941677
Ebitda
-70,257,000.00
-
Enterprise to Ebitda
0.58
Enterprise Value
-40,848,604.00
Target Price
-
Estimated Price
-
Book Value
2.92
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
| Company | Name | Correlation |
|---|---|---|
| 300181.SZ | ZHEJIANG JOLLY PHA | -0.53 |
| 600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | -0.42 |
| IMU.AX | IMUGENE FPO | -0.40 |
| 600866.SS | STAR LAKE BIOSCIENCE CO INC Z | -0.31 |
| 300204.SZ | STAIDSON (BEIJING) | -0.29 |
| 2137.HK | BRII-B | -0.22 |
| ALPHA.PA | PHARNEXT | -0.10 |
| 300009.SZ | ANHUI ANKE BIOTECH | -0.08 |
| 2269.HK | WUXI BIO | -0.08 |
| 1873.HK | VIVA BIOTECH | -0.07 |
| 2370.T | MEDINET CO LTD | -0.05 |
| 0775.HK | CKLIFE SCIENCES | -0.03 |
| 1801.HK | INNOVENT BIO | 0.03 |
| 1530.HK | 3SBIO | 0.04 |
| 1177.HK | SINO BIOPHARM | 0.07 |
| AKBA | Akebia Therapeutics, Inc. | 0.09 |
| 300497.SZ | JIANGXI FUSHINE PH | 0.13 |
| TRX.L | TISSUE REGENIX GROUP PLC | 0.13 |
| 300147.SZ | XIANGXUE PHARMACEU | 0.14 |
| 300363.SZ | PORTON PHARMA SOLU | 0.17 |
| 002007.SZ | HUALAN BIOLOGICAL | 0.23 |
| 600201.SS | JINYU BIO-TECHNOLOGY CO LTD | 0.26 |
| 300122.SZ | CHONGQING ZHIFEI B | 0.31 |
| BLUE | bluebird bio, Inc. | 0.34 |
| 002252.SZ | S/H RAAS BLOOD PRO | 0.38 |
| ATHX | Athersys, Inc. | 0.46 |
| TMBR | Timber Pharmaceuticals, Inc. | 0.60 |
| DNA | Ginkgo Bioworks Holdings, Inc. | 0.61 |
Similar companies
| Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
|---|---|---|---|---|---|---|---|---|---|
| ALPHA.PA | PHARNEXT | Issy-les-Moulineaux | France | EUR | PAR | 2.86 | -0.65 | 40 | https://www.pharnext.com |
| 1177.HK | SINO BIOPHARM | Wan Chai | Hong Kong | HKD | HKG | 0.48 | 17.58 | 25579 | https://www.sinobiopharm.com |
| 0775.HK | CKLIFE SCIENCES | Tai Po | Hong Kong | HKD | HKG | 0.40 | 32.46 | 1855 | https://www.ck-lifesciences.com |
| DNA | Ginkgo Bioworks Holdings, Inc. | Boston | United States | USD | NYQ | -1.24 | 641 | https://www.ginkgobioworks.com | |
| 002252.SZ | S/H RAAS BLOOD PRO | Shanghai | China | CNY | SHZ | 0.21 | 19.62 | 2966 | https://www.raas-corp.com |
| 002007.SZ | HUALAN BIOLOGICAL | Xinxiang | China | CNY | SHZ | 0.03 | 19.25 | 2927 | https://www.hualanbio.com |
| 600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | Suzhou | China | CNY | SHH | 0.56 | -710.43 | https://www.600200.com | |
| 600866.SS | STAR LAKE BIOSCIENCE CO INC Z | Zhaoqing | China | CNY | SHH | 0.35 | 21.35 | 2608 | https://www.starlake.com.cn |
| TRX.L | TISSUE REGENIX GROUP PLC | Garforth | United Kingdom | GBp | LSE | 1.40 | -10.94 | 79 | https://www.tissueregenix.com |
| 2269.HK | WUXI BIO | Wuxi | China | HKD | HKG | 0.91 | 85.17 | 9864 | https://www.wuxibiologics.com |
| IMU.AX | IMUGENE FPO | Sydney | Australia | AUD | ASX | 2.28 | -30.30 | https://www.imugene.com | |
| 600201.SS | JINYU BIO-TECHNOLOGY CO LTD | Hohhot | China | CNY | SHH | 0.31 | 18.76 | 1580 | https://www.jinyu.com.cn |
| TMBR | Timber Pharmaceuticals, Inc. | Basking Ridge | United States | USD | ASE | 0.19 | 5 | https://www.timberpharma.com | |
| 300181.SZ | ZHEJIANG JOLLY PHA | Huzhou | China | CNY | SHZ | 0.10 | 18.50 | 2132 | https://www.zuoli.com |
| CLVS | Clovis Oncology, Inc. | Boulder | United States | USD | NMS | 0.49 | -3.78 | 413 | https://www.clovisoncology.com |
| ATHX | Athersys, Inc. | Cleveland | United States | USD | NCM | -1.30 | -0.60 | 104 | https://www.athersys.com |
| VTGN | VistaGen Therapeutics, Inc. | South San Francisco | United States | USD | NCM | 1.06 | 0.75 | 36 | https://www.vistagen.com |
| 300009.SZ | ANHUI ANKE BIOTECH | Hefei | China | CNY | SHZ | 0.38 | 19.32 | https://www.ankebio.com | |
| 300122.SZ | CHONGQING ZHIFEI B | Chongqing | China | CNY | SHZ | 0.77 | 11.89 | 4800 | https://www.zhifeishengwu.com |
| 2370.T | MEDINET CO LTD | Tokyo | Japan | JPY | JPX | 1.34 | -2.69 | 92 | https://www.medinet-inc.co.jp |
| 2137.HK | BRII-B | Beijing | China | HKD | HKG | -5.41 | 113 | https://www.briibio.com | |
| 1530.HK | 3SBIO | Shenyang | China | HKD | HKG | 0.84 | 6.75 | 5292 | https://www.3sbio.com |
| 1801.HK | INNOVENT BIO | Suzhou | China | HKD | HKG | -0.31 | -14.04 | 5568 | https://www.innoventbio.com |
| 300497.SZ | JIANGXI FUSHINE PH | Jingdezhen | China | CNY | SHZ | 0.14 | 35.19 | 1849 | https://www.fushine.cn |
| 300147.SZ | XIANGXUE PHARMACEU | Guangzhou | China | CNY | SHZ | 0.59 | 374.63 | 3378 | https://www.xphcn.com |
| BLUE | bluebird bio, Inc. | Cambridge | United States | USD | NMS | 1.38 | -0.35 | 518 | https://www.bluebirdbio.com |
| 300204.SZ | STAIDSON (BEIJING) | Beijing | China | CNY | SHZ | 0.16 | -27.06 | 873 | https://www.staidson.com |
| AKBA | Akebia Therapeutics, Inc. | Cambridge | United States | USD | NGM | 1.47 | -0.16 | 426 | https://www.akebia.com |
| 1873.HK | VIVA BIOTECH | Shanghai | China | HKD | HKG | 0.95 | 15.94 | 2127 | https://www.vivabiotech.com.cn |
| 300363.SZ | PORTON PHARMA SOLU | Chongqing | China | CNY | SHZ | -0.36 | 30.90 | 4158 | https://www.porton.cn |
| VLON | Vallon Pharmaceuticals Inc. | Philadelphia | United States | USD | NCM | -1.15 | -0.24 | 2 | https://www.vallon-pharma.com |
| SRNE | Sorrento Therapeutics, Inc. | San Diego | United States | USD | NCM | 2.17 | -2.59 | 799 | https://www.sorrentotherapeutics.com |
| NVAX | Novavax, Inc. | Gaithersburg | United States | USD | NMS | 1.58 | -2.58 | 1541 | https://www.novavax.com |
| 300759.SZ | PHARMARON BEIJING | Beijing | China | CNY | SHZ | 0.28 | 49.23 | 14923 | https://www.pharmaron.com |
| 300404.SZ | BOJI MEDICAL & TEC | Guangzhou | China | CNY | SHZ | -0.10 | 63.41 | 989 | https://www.bojicro.com |
| RIGL | Rigel Pharmaceuticals, Inc. | South San Francisco | United States | USD | NMS | 1.66 | -2.33 | 165 | https://www.rigel.com |
| 688180.SS | SHANGHAI JUNSHI BIOSCIENCES CO | Shanghai | China | CNY | SHH | 0.24 | -39.92 | 2805 | https://www.junshipharma.com |
| 600161.SS | BEIJING TIANTAN BIOLOGICAL PROD | Beijing | China | CNY | SHH | 0.02 | 23.29 | 3933 | https://www.tiantanbio.com |
| 9939.HK | KINTOR PHARMA-B | Suzhou | China | HKD | HKG | -0.77 | -5.99 | 316 | https://www.kintor.com.cn |
| VERU | Veru Inc. | Miami | United States | USD | NCM | -0.41 | -41.18 | 252 | https://www.verupharma.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.